NYSE American - Delayed Quote USD
Chromocell Therapeutics Corporation (CHRO)
At close: October 21 at 3:59 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-5,558.3500
-981.0310
-1,567.1490
-1,593.0110
-3,625.7730
Financing Cash Flow
7,881.5550
1,022.3480
1,622.2230
1,593.0110
3,625.7730
End Cash Position
2,405.0980
96.3910
55.0740
--
--
Issuance of Capital Stock
6,227.4120
255.4120
--
--
--
Issuance of Debt
1,960.4120
766.9360
400.0000
--
241.7930
Free Cash Flow
-5,558.3500
-981.0310
-1,567.1490
-1,593.0110
-3,625.7730
12/31/2020 - 2/16/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
GRI GRI Bio, Inc.
1.3200
+127.59%
WINT Windtree Therapeutics, Inc.
1.0700
+17.16%
SLRX Salarius Pharmaceuticals, Inc.
1.8200
-9.45%
KLTO Klotho Neurosciences, Inc.
0.7103
-6.22%
PHIO Phio Pharmaceuticals Corp.
3.1800
+9.28%
NTBL Notable Labs, Ltd.
0.3428
+10.58%
SCPX Scorpius Holdings, Inc.
0.8238
+0.46%
CMND Clearmind Medicine Inc.
1.5400
-12.25%
ENTO Entero Therapeutics, Inc.
0.6800
-8.03%
GNPX Genprex, Inc.
1.5100
+260.38%